Abstract
Between October 1993 and September 1994, 33 women with metastatic breast cancer aged between 29 and 74 years with a median age of 58 were entered into a study of oral chemotherapy from three UK centres. Patients by definition had metastatic disease and were fit and well with performance status 0 or 1 in 23 cases, 2 in seven cases and 3 in two cases (one missing). Five patients had received prior adjuvant CMF chemotherapy, nine first line non-anthracycline containing chemotherapy for relapse, eight patients second line non-anthracycline containing chemotherapy and all patients had had hormone therapy either as adjuvant or for relapsed disease. Adjuvant radiotherapy had been given to 17 and palliative radiotherapy to 12 patients. In nine patients there was one site of disease at start of therapy, in 10 two sites, in 11 three sites and in three patients four or more sites. The regimen comprised oral idarubicin 15 mg/m2 on day 1, 10 mg/m2 on days 2 and 3 and oral cyclophosphamide 250 mg/m2 (maximum 400 mg) on days 1, 2 and 3. Treatment was continued until disease progression or toxicity.
Original language | English |
---|---|
Pages (from-to) | 61-6 |
Number of pages | 6 |
Journal | Critical Reviews in Oncology/Hematology |
Volume | 33 |
Issue number | 1 |
Publication status | Published - Jan 2000 |
Keywords / Materials (for Non-textual outputs)
- Administration, Oral
- Adult
- Aged
- Agranulocytosis
- Antibiotics, Antineoplastic
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Cyclophosphamide
- Disease Progression
- Fatigue
- Female
- Humans
- Idarubicin
- Infection
- Middle Aged
- Thrombocytopenia